Loading Events

Rare Bone Disease Working Group
October 7, 2021
4:00 to 7:30 PM U.S. Eastern Time

Chair – Matthew Warman, MD, Boston Children’s Hospital
Supported by the Rare Bone Disease Alliance, a program of the Osteogenesis Imperfecta Foundation
and unrestricted educational grants from Inozyme Pharma, IPSEN, BioMarin Pharmaceutical Inc. and Ultragenyx Pharmaceutical.

Registration: When you register for the 2021 ASBMR Annual Meeting, also register for the Working Group. There is no separate registration fee for the Working Group.


PROGRAM:

4:00 PM Welcome and Introductions
Matthew Warman

4:10 PM PIK3CA Inhibition in patients with CLOVES syndrome and other PI3K-related overgrowth spectrum diseases
Guillaume Canaud, Necker Hospital, Paris, France

4:40 PM A pan-AKT inhibitor for patients with Proteus syndrome
Chris Ours, National Institutes of Health, Bethesda, MD, USA

5:05 PM IDH1/2 Inhibitors as potential therapies for patients with Ollier or Maffucci syndrome
Elizabeth Alva, University of Alabama, Birmingham, AL, USA

5:30 PM Gorham-Stout and Generalized Lymphatic Anomaly-Clinical Aspects
Gulraiz Chaudry, Boston Children’s Hospital, Boston, MA, USA

5:50 PM Insights into lymphatic-mediated bone destruction from a mouse model
Michael Dellinger, University of Texas Southwestern, Dallas, TX, USA

6:10 PM Multicentric Carpotarsal Osteolysis syndrome (MCTO)-Clinical Aspects
Nina Ma, University of Colorado School of Medicine, Denver, CO, USA

6:30 PM Insights into MCTO from a mouse model
Satoru Takahashi, Tsukuba University, Tskuba, Japan

6:50 – 7:30PM Questions and Discussion


If you are not attending the ASBMR Meeting but wish to participate in the Working Group program, please contact Charlene Waldman at waldmancharlene234@gmail.com.

Details

Date:
October 7, 2021
Time:
4:00 pm - 7:30 pm
Event Category: